vs
Side-by-side financial comparison of Hillman Solutions Corp. (HLMN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $370.1M, roughly 1.7× Hillman Solutions Corp.). Royalty Pharma plc runs the higher net margin — 34.4% vs -1.3%, a 35.7% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 3.0%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -1.2%).
Hillman Solutions is an American hardware manufacturing, distribution and consumer fabrication services company.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
HLMN vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $370.1M | $622.0M |
| Net Profit | $-4.7M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 1.9% | 62.4% |
| Net Margin | -1.3% | 34.4% |
| Revenue YoY | 3.0% | 4.8% |
| Net Profit YoY | — | 2.9% |
| EPS (diluted) | $-0.02 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $370.1M | — | ||
| Q4 25 | $365.1M | $622.0M | ||
| Q3 25 | $424.9M | $609.3M | ||
| Q2 25 | $402.8M | $578.7M | ||
| Q1 25 | $359.3M | $568.2M | ||
| Q4 24 | $349.6M | $593.6M | ||
| Q3 24 | $393.3M | $564.7M | ||
| Q2 24 | $379.4M | $537.3M |
| Q1 26 | $-4.7M | — | ||
| Q4 25 | $1.6M | $214.2M | ||
| Q3 25 | $23.2M | $288.2M | ||
| Q2 25 | $15.8M | $30.2M | ||
| Q1 25 | $-317.0K | $238.3M | ||
| Q4 24 | $-1.2M | $208.2M | ||
| Q3 24 | $7.4M | $544.0M | ||
| Q2 24 | $12.5M | $102.0M |
| Q1 26 | 1.9% | — | ||
| Q4 25 | 4.6% | 62.4% | ||
| Q3 25 | 10.8% | 70.1% | ||
| Q2 25 | 9.0% | 36.3% | ||
| Q1 25 | 4.2% | 94.0% | ||
| Q4 24 | 4.0% | 60.9% | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 8.3% | 50.2% |
| Q1 26 | -1.3% | — | ||
| Q4 25 | 0.4% | 34.4% | ||
| Q3 25 | 5.5% | 47.3% | ||
| Q2 25 | 3.9% | 5.2% | ||
| Q1 25 | -0.1% | 41.9% | ||
| Q4 24 | -0.3% | 35.1% | ||
| Q3 24 | 1.9% | 96.3% | ||
| Q2 24 | 3.3% | 19.0% |
| Q1 26 | $-0.02 | — | ||
| Q4 25 | $0.00 | $0.49 | ||
| Q3 25 | $0.12 | $0.67 | ||
| Q2 25 | $0.08 | $0.07 | ||
| Q1 25 | $0.00 | $0.55 | ||
| Q4 24 | $-0.00 | $0.46 | ||
| Q3 24 | $0.04 | $1.21 | ||
| Q2 24 | $0.06 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.7M | $618.7M |
| Total DebtLower is stronger | $714.1M | $9.0B |
| Stockholders' EquityBook value | $1.2B | $9.7B |
| Total Assets | $2.4B | $19.6B |
| Debt / EquityLower = less leverage | 0.59× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $27.7M | — | ||
| Q4 25 | $27.3M | $618.7M | ||
| Q3 25 | $37.7M | $938.9M | ||
| Q2 25 | $34.2M | $631.9M | ||
| Q1 25 | $36.3M | $1.1B | ||
| Q4 24 | $44.5M | $929.0M | ||
| Q3 24 | $59.8M | $950.1M | ||
| Q2 24 | $54.0M | $1.8B |
| Q1 26 | $714.1M | — | ||
| Q4 25 | $668.3M | $9.0B | ||
| Q3 25 | $683.2M | $8.9B | ||
| Q2 25 | $683.1M | $8.0B | ||
| Q1 25 | $713.5M | $7.6B | ||
| Q4 24 | $691.7M | $7.6B | ||
| Q3 24 | $730.7M | $7.6B | ||
| Q2 24 | $732.1M | $7.6B |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.2B | $9.8B | ||
| Q4 24 | $1.2B | $10.3B | ||
| Q3 24 | $1.2B | $10.3B | ||
| Q2 24 | $1.2B | $9.8B |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $19.6B | ||
| Q3 25 | $2.4B | $19.3B | ||
| Q2 25 | $2.4B | $18.3B | ||
| Q1 25 | $2.3B | $17.6B | ||
| Q4 24 | $2.3B | $18.2B | ||
| Q3 24 | $2.4B | $18.0B | ||
| Q2 24 | $2.4B | $17.7B |
| Q1 26 | 0.59× | — | ||
| Q4 25 | 0.54× | 0.92× | ||
| Q3 25 | 0.56× | 0.93× | ||
| Q2 25 | 0.57× | 0.84× | ||
| Q1 25 | 0.60× | 0.78× | ||
| Q4 24 | 0.59× | 0.74× | ||
| Q3 24 | 0.62× | 0.74× | ||
| Q2 24 | 0.62× | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | $-34.3M | — |
| FCF MarginFCF / Revenue | -9.3% | — |
| Capex IntensityCapex / Revenue | 4.0% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $22.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.9M | $827.1M | ||
| Q3 25 | $26.2M | $702.6M | ||
| Q2 25 | $48.7M | $364.0M | ||
| Q1 25 | $-655.0K | $596.1M | ||
| Q4 24 | $43.1M | $742.5M | ||
| Q3 24 | $63.7M | $703.6M | ||
| Q2 24 | $64.8M | $658.2M |
| Q1 26 | $-34.3M | — | ||
| Q4 25 | $16.1M | — | ||
| Q3 25 | $9.1M | — | ||
| Q2 25 | $31.2M | — | ||
| Q1 25 | $-21.3M | — | ||
| Q4 24 | $22.1M | — | ||
| Q3 24 | $39.6M | — | ||
| Q2 24 | $42.5M | — |
| Q1 26 | -9.3% | — | ||
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | -5.9% | — | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 10.1% | — | ||
| Q2 24 | 11.2% | — |
| Q1 26 | 4.0% | — | ||
| Q4 25 | 4.0% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 5.7% | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 5.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.33× | 3.86× | ||
| Q3 25 | 1.13× | 2.44× | ||
| Q2 25 | 3.08× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 8.57× | 1.29× | ||
| Q2 24 | 5.17× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HLMN
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
